Jaguar Health, Inc. (NASDAQ:JAGX – Get Free Report) was the recipient of a large decline in short interest during the month of October. As of October 15th, there was short interest totalling 139,400 shares, a decline of 66.2% from the September 30th total of 413,000 shares. Currently, 1.8% of the shares of the stock are short sold. Based on an average daily volume of 397,600 shares, the days-to-cover ratio is currently 0.4 days.
Wall Street Analyst Weigh In
Separately, StockNews.com raised shares of Jaguar Health from a “sell” rating to a “hold” rating in a research note on Friday, September 13th.
Read Our Latest Stock Analysis on Jaguar Health
Jaguar Health Price Performance
Jaguar Health (NASDAQ:JAGX – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($4.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($2.84). The business had revenue of $2.72 million for the quarter. Jaguar Health had a negative return on equity of 412.63% and a negative net margin of 350.18%. As a group, equities analysts forecast that Jaguar Health will post -0.78 earnings per share for the current year.
Institutional Trading of Jaguar Health
An institutional investor recently bought a new position in Jaguar Health stock. Perritt Capital Management Inc purchased a new stake in shares of Jaguar Health, Inc. (NASDAQ:JAGX – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 25,000 shares of the biotechnology company’s stock, valued at approximately $90,000. Perritt Capital Management Inc owned 0.51% of Jaguar Health at the end of the most recent quarter. 12.04% of the stock is owned by institutional investors.
About Jaguar Health
Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.
Featured Articles
- Five stocks we like better than Jaguar Health
- What is the Euro STOXX 50 Index?
- Texas Roadhouse Stock Steering for New Highs This Year
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How to invest in marijuana stocks in 7 stepsĀ
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.